APS_ACTION

@APS_ACTION 2025 Young Scholar Zeynep Belce Erton from @HSpecialSurgery Presenting her Research During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan).

@APS_ACTION Scientific Session and Poster Presentations During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan). Thank you to all the presenters and session participants.

Congratulations to 2025 APSACTION Silvia Pierangeli Young Scholar Award (in collaboration with APS Foundation of America) Recipients: Alice Barinotti, Zeynep Erton, Alex Luta, Liala Moschetti, Andrew Song. During #ICAPA25, Alice and Zeynep received their certificates in person.

Most Recent APS ACTION Publication: pubmed.ncbi.nlm.nih.gov/40737058/

Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION. pubmed.ncbi.nlm.nih.gov/39895040/

Survey Reveals 60% Satisfaction with DIAPS but Highlights Need for Improvements: cutt.ly/ge3C9xa4 @APS_ACTION @DorukErkanMD

2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification c… pubmed.ncbi.nlm.nih.gov/39395544/

Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prosp… pubmed.ncbi.nlm.nih.gov/38185079/

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical … pubmed.ncbi.nlm.nih.gov/39423147/

Damage Index for Antiphospholipid Syndrome (DIAPS): An Antiphospholipid Syndrome Alliance for Clinical Trials and I… pubmed.ncbi.nlm.nih.gov/39662300/

HSS investigators presented new research findings in #antiphospholipidsyndrome at the @ACRheum Convergence 2024 meeting. #ACR24 #HSSRhem @DorukErkanMD @APS_ACTION news.hss.edu/new-antiphosph…

🤔🩸🔮 Rethinking antiphospholipid syndrome to guide future management and research @NatRevRheumatol @DorukErkanMD nature.com/articles/s4158…

Our most recent publication on thrombosis recurrence and major bleeding risk in non-anticoagulated thrombotic antiphospholipid syndrome patients. We want to thank all APS ACTION members for their contributions. pubmed.ncbi.nlm.nih.gov/38185079/

ICYMI: In this #RPTH Commentary @crowthrm and @DorukErkanMD discuss the new ACR/EULAR 2023 #Antiphospholipid Syndrome classification and how it may be applied across different clinical scenarios! Read here➡️: rpthjournal.org/article/S2475-…

#ACR23 Recap: @dorukerkanmd and @jasonsknight explained the antiphospholipid syndrome classification criteria developed by the ACR and EULAR. Read more in ACR Convergence Today → acr.tw/3N6aY5v

Antiphospholipid Syndrome Diagnosis versus Classification. What is the Difference? The answer is in this recently updated @HSpecialSurgery Top 10 Series Patient Web Article hss.edu/conditions_top…

Today we have award-winning #APS researcher @DorukErkanMD with us, who explains the importance of creating new classification criteria for APS & what the proper use of them ought to be! Listen → acronair.org #ACR23

@APS_ACTION Core Laboratories Presented at #ACR23 Their Performance Assessment of LA Testing Using TSVT/ECT. acrabstracts.org/abstract/perfo….

Dr Alexander Pine Presenting at #ACR23 - @APS_ACTION & Yale School of Medicine Collaboration on Antiphospholipid Syndrome and Plasma Proteomic Profiling acrabstracts.org/abstract/plasm…

Dr Cecile Yelnik presenting at #ACR23 on Behalf of @APS_ACTION - Antiphospholipid Syndrome (#APS) & Complement Pathway Activation acrabstracts.org/abstract/compl….